Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486001 · ClinicalTrials.gov registry record · Phase 1
Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19
A Phase 1 study, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04486001 is a Phase 1 study that has completed, run by Sorrento Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT04486001, a Phase 1 study, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic environment. This data will be used for FDA IND filings and pursuit of a BLA.
Interventions
- BIOLOGICAL PSC-04
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2021-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04486001
The ClinicalTrials.gov registry entry for NCT04486001 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PSC-04 is the first listed.
NCT04486001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04486001 about?
NCT04486001 is a clinical study titled "Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19". This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic environment. This data will be used for FDA IND filings and pursuit of a BLA.
What is the current status of trial NCT04486001?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-12-15. Estimated completion is 2021-08-30.
What interventions are being tested in trial NCT04486001?
The interventions under investigation include: PSC-04 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04486001?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.